ArticleWorld journal of transplantation2026
Long-term renal function and complication profiles after ABO-incompatible
Article in World journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundABO-incompatible (ABOi) kidney transplantation expands the living-donor pool but may increase immunologic and infectious risks. Advances in desensitization have improved outcomes, yet long-term comparative data remain limited. We hypothesized that ABOi living-donor kidney transplantation achieves renal function and complication rates comparable to ABO-compatible (ABOc) procedures under modern protocols.
aimTo assess whether long-term renal function and complication profiles remain comparable between ABOi and ABOc living-donor kidney transplant recipients.
methodsA retrospective single-center cohort study was conducted in a Portuguese transplant program, including all adult living-donor kidney transplants from January 2014 to December 2022 (follow-up to June 2023). A total of 208 recipients were included: 22 ABOi and 186 ABOc, excluding human leukocyte antigen-incompatible or high immunologic risk cases. Continuous variables were compared using Mann-Whitney
resultsMedian follow-up was 57 months. Five-year patient survival was 92.9% [95% confidence interval (CI): 79.4-100] in ABOi and 90.3% (95%CI: 85.5-95.2) in ABOc (
conclusionABOi transplantation achieved outcomes comparable to ABOc living-donor transplantation under contemporary desensitization protocols. These findings support the safety and efficacy of ABOi transplantation, while ongoing multicenter follow-up is needed to confirm long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.